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Marjo L. Yliperttula,▽▽ Natasa Zarovni,⬢⬢ Apolonija Bedina Zavec,□□ and Bernd Giebel*,■■
†Anti-Tumor Drugs Section, Department of Therapeutic Research and Medicines Evaluation, National Institute of Health (ISS),
00161 Rome, Italy
‡School of Pharmacy and Pharmaceutical Sciences & Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2,
Ireland
§IVECAT-Group, Germans Trias i Pujol Research Institute (IGTP), and Nephrology Service, Germans Trias i Pujol University
Hospital, Campus Can Ruti, 08916 Badalona, Spain
∥Department of Genetics, Cell- and Immunobiology, Semmelweis University, 1085 Budapest, Hungary
⊥Molecular Biotechnology Center, Department of Medical Sciences, University of Turin, 8 Turin, Italy
#Human Anatomy Section, Department of Experimental Biomedicine and Clinical Neuroscience, University of Palermo, and
Euro-Mediterranean Institute of Science and Technology, 90133 Palermo, Italy
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∮ Prof. Ephraim Katzir Department of Biotechnology
Engineering, ORT Braude College, Karmiel 2161002, Israel
∞Dept. of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital−The Norwegian Radium Hospital, 0379
Oslo, Norway
@Institute for Environmental Health Sciences and Hospital Infection Control, Medical Center University of Freiburg, 79106 Freiburg
am Breisgau, Germany
‡‡Mass Spectrometry and Proteomics, Institute of Biosciences and BioResources, National Research Council of Italy, 80131 Naples, Italy
§§Systems and Cell Biology of Neurodegeneration, University of Zurich, 8006 Zurich, Switzerland
⊥⊥Institut Curie, PSL Research University, UMR144, Centre de Recherche, 26 rue d’ULM, and Centre National de la Recherche
Scientifique, UMR144, 75231 Paris, France
¶¶Spinal Cord Injury & Tissue Regeneration Center Salzburg (SCI-TReCS), Paracelsus Medical University (PMU), 5020 Salzburg, Austria
△△Department of Blood Group Serology and Transfusion Medicine, University Hospital, Salzburger Landeskliniken GesmbH
(SALK), 5020 Salzburg, Austria
▲▲Division of Biochemistry and Biotechnology, Department of Biosciences, and ▽▽Division of Pharmaceutical Biosciences,
Faculty of Pharmacy, University of Helsinki, 00100 Helsinki, Finland
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ABSTRACT: Recent research has demonstrated that all
body fluids assessed contain substantial amounts of vesicles
that range in size from 30 to 1000 nm and that are
surrounded by phospholipid membranes containing differ-
ent membrane microdomains such as lipid rafts and
caveolae. The most prominent representatives of these
so-called extracellular vesicles (EVs) are nanosized exo-
somes (70−150 nm), which are derivatives of the endosomal
system, and microvesicles (100−1000 nm), which are
produced by outward budding of the plasma membrane.
Nanosized EVs are released by almost all cell types and
mediate targeted intercellular communication under physiological and pathophysiological conditions. Containing cell-type-
specific signatures, EVs have been proposed as biomarkers in a variety of diseases. Furthermore, according to their physical
functions, EVs of selected cell types have been used as therapeutic agents in immune therapy, vaccination trials, regenerative
medicine, and drug delivery. Undoubtedly, the rapidly emerging field of basic and applied EV research will significantly
influence the biomedicinal landscape in the future. In this Perspective, we, a network of European scientists from clinical,
academic, and industry settings collaborating through the H2020 European Cooperation in Science and Technology (COST)
program European Network on Microvesicles and Exosomes in Health and Disease (ME-HAD), demonstrate the high potential
of nanosized EVs for both diagnostic and therapeutic (i.e., theranostic) areas of nanomedicine.
Strategic platforms for nanomedicine seek to exploit theimproved (and often novel) physical, chemical, andbiological properties of nanomaterials. However, these
documents specify that there is an urgent need for biomimetism,
namely, the process of simulating what occurs in nature.1−3
Extracellular vesicles (EVs), such as exosomes and small
microvesicles, are nanovesicles, naturally released from cells in
both normal or diseased states. Reflecting their cells of origin,
these EVs are assembled by specific sets of molecules including
proteins, lipids, metabolites, and nucleic acids. According to
their molecular signature, they are able to interact specifically
with selected target cells at local or distant sites, within or
between organs.4 Considered to be a vectorized signaling system,
they seem to bind to specific membrane microdomains on their
target cells; among others, these membrane microdomains
contain transmembrane receptors, integrins, and cell-adhesion
molecules. To transmit their information, they either fuse with
the plasma membrane or get incorporated by endocytotic
processes (Figure 1). Thus, in addition to direct cell−cell
contact and soluble factors (e.g., cytokines, chemokines, and
hormones), EV-mediated signaling provides a third complex
and targeted mode of intercellular communication.5 According
to their features, EVs are ideal candidates to serve
as biomarkers, nanosized drug-delivery vehicles, and mediators
for a variety of therapeutics in oncology, immune therapy, and
regenerative medicine.4,6 Thus, EVs have the potential for great
clinical impact in nanomedicine. The dual potential of EVs
as diagnostic tools and as therapeutic agents supports their
use in “theranostics”. This area of nanomedicine focuses on
multidisciplinary research to set up new systems for various
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nanobiomedical applications, ranging from the medical use of
nanoplatform-based diagnostic agents, to therapeutic agents,
to possible future applications of diagnosis and therapy.7
Theranostics includes the early detection of diseases, the
monitoring of therapeutic responses, and the targeted delivery
of therapeutic agents. Theranostics at the nanoscale encom-
passes nanoprobes, nanocarriers, and nanodiagnostics. How-
ever, the most important task of a theranostic strategy concerns
theranostic nanoformulations, which deal with the develop-
ment of new agents based on a “whole-in-one approach”, which
should have maximal application in the field of personalized
medicine. Extracellular vesicles appear to be ideal nanovectors
for theranostics, with maximal potential for targeting the
disease site with only minimal side effects. If successful, the
proof-of-concept in the use of EVs as autologous or allogeneic
nanovectors for both diagnosis and therapy of major diseases
will enable widespread preclinical and clinical applications.
NANOSIZED EXTRACELLULAR VESICLES AS DISEASE
BIOMARKERS
In this section, we present data supporting the future of
nanosized EVs as potentially the most reliable biomarkers in
medicine. The majority of the available clinical data have been
obtained from studies of cancer patients. However, based on
the more limited data emerging from studies of other patho-
logies, the ensemble of the data supports EVs found in bodily
fluids as a source of biomarkers for all human diseases evaluated
thus far. The current “equipment” of disease biomarkers
represents an unmet clinical need, and so far, many approaches
have searched for single molecules as biomarkers. As an example,
prostate-specific antigen (PSA) is a prominent molecule that is
used as a prostate cancer (PCa) marker. Plasma PSA
determination is now used worldwide in PCa screening, and it
rapidly replaced digital rectal examination for early detection of
cancer.8,9 Plasma PSA is controversial as a PCa biomarker,
however,10−12 due to the likelihood of false positives, including
benign prostatic hyperplasia (BPH).11 Since PSA testing fails to
discriminate between BPH and tumors, the use of this analysis
causes overdiagnosis and overtreatment with consequent patients
suffering side effects.11,13−15 Prostate-specific antigen values
above 4.0 ng per milliliter are considered abnormal; however,
cutoff levels can change with age, race, and individual
physiological condition,11,13,14 with no significant progress in
the last decades.16 As multimolecular aggregates, EVs offer the
unique opportunity to use a combination of different markers
specifically expressed on tumor-derived EVs. In fact, serum PSA
has been detected on plasma and urine- derived EVs in a large
clinical study.17,18
Tumors. Tumor-derived EVs are proposed to contain a
tumor-specific molecular signature, qualifying them as potential
biomarkers in tumor diagnostics.19 Such EVs can be harvested
from biofluids such as blood and, for some cancer types, urine.
In addition to PSA, clinical studies on other EV-associated
cancer biomarkers have already been described and are
summarized in Table 1. For example, a retrospective study
on EV-associated biomarkers in stages III and IV melanoma
patients showed increased levels of plasmatic caveolin-1 and
CD63-positive EVs.20 Researchers found that EV-associated
caveolin-1 displayed a sensitivity of 69% and specificity of
96.3%, whereas a conventional cancer biomarker used in the
follow up of melanoma patients, such as lactate dehydrogenase
(LDH) serum levels, was altered in only 12.5% of patients.20
More recently, a study in patients with pancreatic cancer found
that glypican-1 (GPC1)-positive EVs were detectable in the
serum of patients with pancreatic cancer with high levels of
specificity and sensitivity and could distinguish healthy subjects
and patients with a benign pancreatic disease from patients with
early- and late-stage pancreatic cancer.21 Moreover, breast cancer
patients also presented high levels of GPC1 on EVs, suggesting
that an increase of certain EV subtypes might represent a hallmark
Figure 1. Exosomes, a natural source of nanoparticles to target cell membranes and deliver bioactive molecules or to be analyzed for
biomarkers. (A) Extracellular vesicles are 50−300 nm vesicles surrounded by a lipid bilayer. Such physical characteristics are uniquely observed
by cryo-electron microscopy (exemplified by a picture of exosomes derived from a human melanocytic cell line observed by cryo-EM. Credit:
G. van Niel and A. Di Cicco. (B) Schematic representation of extracellular vesicles and the potential bioactive molecules and biomarkers that
can be associated. Families of molecules of interest are classified by color codes as detailed in the text beneath. Credit: G. van Niel.
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of malignant cancers in general. In fact, EV concentration could
also be used as an indicator of clinical status. For example,
when the effect of treatment with imatinib due to a gastro-
intestinal stromal tumor was monitored, researchers found that
the concentration of EVs before the treatment was increased
with respect to the control.22 Elevated levels of EV-expressing
TYRP-2, VLA- 4, HSP70, and HSP90 have been detected in the
plasma of melanoma patients.23 Both HSP70 and HSP90
belong to the family of heat shock proteins (HSPs), which may
emerge as a novel class of EV-associated cancer biomarkers.19
Remarkably, EV-associated levels of HSP60 were dramatically
decreased in colon cancer patients after surgical removal of the
tumor.24 As previously mentioned, EVs may also shuttle well-
known tumor markers such as PSA. The EV-associated biomarker
survivin has also been identified as a promising surrogate bio-
marker for early diagnosis of PCa.25 Furthermore, in PCa
patients, the EV concentration, as measured by nanoparticle
tracking analysis (NTA), is higher than that in the plasma of
healthy controls.26 Interesting results were obtained by comparing
N-glycan profiles of EVs from indolent and aggressive prostate
cancer to those from noncancerous profiles.27 Other series of
clinical data of paramount importance are summarized in Table 1.
Table 1. Clinical Data Showing the Role of Nanosized Extracellular Vesicles as Tumor Biomarkers
cancer biomarker indication biofluid clinical study size ref
PSA prostate cancer screening/early
diagnosis
urine controls N = 10; disease N = 24 17
PSA prostate cancer screening/early
diagnosis
plasma control N = 2; disease N = 5 18
EGFRvIII glioblastoma early diagnosis serum disease N = 30 137
(phospho)Met melanoma early diagnosis/
prognosis
plasma Controls N = 7; stage III N = 24; stage IV
N = 14
23
caveolin-1 melanoma early diagnosis plasma controls N = 58; disease N = 90 20
survivin prostate cancer early diagnosis olasma HD N = 8; BPH N = 20; disease N = 39 25
CD24 breast cancer early diagnosis serum HD N = 14, disease N = 18 138
EGRF lung cancer diagnosis/
personalized
medicine
serum HD N = 9; disease N = 9 139
miR-21, miR-141, miR-200a, miR-200b,
miR-200c, miR-203, miR-205, miR-214
ovarian cancer early diagnosis/
prognosis
serum HD N = 10; stage I N = 10; stage II N = 10;
stage III N = 20; stage IV N = 10
140
RNU6-1, miR-320, and miR-574-3p glioblastoma early diagnosis serum controls N = 50; disease N = 50 141
TMPRSS2:ERG2 and PCA3 mRNAs prostate cancer early diagnosis urine blinded prospective study N = 30 142
let-7a, miR-1229, miR-1246, miR-150,
miR-21, miR-223, and miR-23a
colorectal cancer early diagnosis serum controls N = 22; disease N = 88 142
miR-21, miR1225-5p gastric cancer prognosis peritoneal
lavage fluid
disease N = 24 28
methylated LINE1 and SOX17 DNA gastric cancer diagnosis gastric juice HD N = 10; disease N = 20 143
CCR6 and HER-2/neu gastric cancer prognosis plasma HD N = 10; disease N = 37 144
miR-151a-5p, miR-30a-3p, miR-200b-5p,
miR-629, miR-100, and miR-154-3p
lung cancer early diagnosis plasma HD N = 10; benign disease N = 10;
malignant disease N = 10
145
TGFB1 and MAGE3/6 ovarian cancer prognosis/therapy
monitoring
plasma HD N = 10; benign disease N = 10;
malignant disease N = 22
146
TYRP2, HSP70, HSC70, VLA-4 melanoma prognosis plasma HD N = 9; stage I N = 2; stage III N = 7;




prognosis serum HD N = 41; disease N = 51 147
KRAS pancreatic cancer personalized
medicine
serum HD N = 2; disease N = 2 148




plasma in vivo model N = 8 96
Glypican-1 pancreatic cancer early diagnosis serum HD N = 100; disease N = 190 21
Glypican-1 breast cancer early diagnosis serum HD N = 100; disease N = 32 21
Hsp60 colon cancer early diagnosis/
follow up
plasma controls N = 40; disease N = 57 Cappello




urine controls N = 23; RCC N = 29 149
EDIL-3/Del1 bladder cancer diagnostic/
prognostic?
urine controls N = 12; patients N = 12 150
Presence: LASS2, GALNT1
bladder cancer diagnosis urine controls N = 11; patients N = 8 151
Absence: ARHGEF39 and FOXO3
TACSTD2 bladder cancer diagnosis urine controls N = 29; patients N = 37 152
ITGA3 and ITGB1 metastatic prostate
cancer
detection urine patients with BPH (N = 5), PCa (N = 5),
and metastatic PCa (N = 3)
153
miR-34a prostate cancer response to
treatment
urine controls N = 36; patients N > 100 (different
disease stage)
154
TM256, ADIRF, LAMTOR1 and others. prostate cancer diagnosis/follow
up
urine controls N = 15; prostate cancer N = 16 155
AGR2 splice variants prostate cancer screening/early
diagnosis
urine BPH N = 15; prostate cancer N = 24 156
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Interestingly, in addition to plasma and serum biofluids, other
biofluids may represent valuable sources of EV biomarkers.
Peritoneal lavage and gastric juice, for example, may represent
promising, noninvasive, and informative sources for gastric
cancer diagnosis and/or follow up.28
Bronchoalveolar lavage (BALF) is an excellent bioresource
for studying lung disorders, including cancer. Bronchoalveolar
lavage contains EVs with the morphology, density range, and
cargo with different size and vesicular forms compared to that
of lung surfactant aggregates. In humans, EVs recovered from
BALF of healthy individuals were shown to contain major
histocompatibility complex (MHC) molecules that may
regulate the local immune defense.29 In sarcoidosis, however,
the quantity of EVs is increased and they present a relatively
greater quantity of MHC class I and class II molecules, as well as
other bioactive molecules, such as neuregulin-1. Furthermore, they
can activate autologous cells to produce inflammatory cytokines.30
In asthma, BALF EVs exhibit particular microRNA (miRNA)
profiles31 and carry the biosynthetic machinery for leukotriene
biosynthesis. Different miRNA contents were found in BALF
from non-small-cell lung cancer compared to that from plasma.32
Extracellular vesicles have also been isolated from nasal lavage
fluid and can be used for studying upper airway diseases.33
Urinary EVs have also gained much attention as a source of
biomarkers, as urine can be collected noninvasively in large
amounts, and the isolated EVs are as stable as those from other
biofluids. Urine contains highly heterogeneous populations of
EVs that are released by the epithelial cells of the genitourinary
system,34,35 and the molecular profiles of urinary EVs seem to
directly reflect the pathophysiological state of this system.
Therefore, EV-based diagnosis could represent an alternative to
current diagnostics, which, for many diseases of the genito-
urinary system (kidney, bladder, prostate), rely on poorly
predictive, relatively inaccurate biomarkers and/or on biopsy,
which is associated with patient morbidity. Recently described
isolation, purification,36 and analytical strategies for urinary EVs
facilitate their in-depth molecular characterization in research
settings37,38 and also in hospital settings.39 During pathogenesis,
the released EVs are subjected to disease-specific alterations
that can be detected by in-depth proteomic, transcriptomic
miRNA analyses or by metabolomics studies35 to reveal the
disease-specific markers that may be validated in preclinical and
clinical diagnostic platforms. Notably, studies of the molecular
composition of urinary EVs have not been restricted to cancer.
Extracellular vesicles may also provide a reliable source of
molecules to help understand the metabolic and physiologic
state of the urinary tract, providing suitable biomarkers for
diseases such as kidney injury, glomerulonephritis, lupus
nephritis, diabetic nephropathy, thin basement membrane
nephropathy, polycystic kidney disease, and/or fibrosis.35
Neurodegenerative Diseases. Extracellular vesicles have
been implicated in various neurodegenerative diseases including
Alzheimer’s disease (AD), Parkinson’s, and amyotrophic lateral
sclerosis. Central nervous system resident neural and non-neural
cells all release EVs that can be detected in biological fluids,
thus constituting a potentially beneficial source of information.
In recent years, several groups have investigated EVs in blood
and cerebrospinal fluid (CSF) during neurological diseases.40
In several cases, EV analysis is progressing to the clinic despite
numerous technological limitations. Among stroke victims,
several studies have reported that endothelium and platelets
under stress conditions release EVs, whose increase in plasma is
proportional to ischemic brain volume.41 In neurodegenerative
disorders, the release of neurotoxic protein aggregates in
association with EVs has been reported,42 and further
investigations have explored the roles of EVs in the pathogenesis
of these diseases.43 In fact, an interesting feature of neuro-
degenerative diseases is that they are characterized by the
deposition of certain misfolded proteins into amyloid/amyloid-
like aggregates in distinct regions of the brains. The misfolded
versions of the proteins are suggested to be the primary culprits
in the pathogenesis of AD, for instance. Amyloid proteins are,
in fact, released in association with EVs, fully in agreement with
the intracellular pathways of amyloid-associated proteins. Both
immunoelectron microscopy and density gradient separation of
EVs demonstrate that they contain Aβ peptides, suggesting that
cells released some of the Aβ peptides in association with EVs,
which can enable further deposition of peptides into amyloid
plaques or even facilitate long-range transport. Evidence that
EVs can participate in the formation of amyloid plaques came
from the observation that EVs contain many pro-amyloidogenic
lipids such as cholesterol, gangliosides, and sphingolipids,
further supporting the hypothesis that they may participate in
amyloid formation. While many of the underlying studies
indicate detrimental roles of EVs in promoting amyloids, there is
some controversy in this regard, as EVs have also been proposed to
have a protective role by aiding in the clearance of amyloids.44,45
Extracellular vesicles detected in the CSF are also suggested to be
a potential source of biomarkers for patients with dementia.46
Similarly, in patients affected by neuroinflammatory diseases such
as multiple sclerosis, CSF EVs have been proposed as biomarkers
for microglia activation, with the possibility of revealing the
activation type (i.e., protective or detrimental), along with disease
progression.47 Finally, seminal work has shown that glioblastoma
EVs can be detected in plasma and reflect the corresponding
brain tumor volume and its response to treatment, which is an
extraordinary potential advancement over invasive brain biopsies
or repeated imaging of the brain.48 These studies suggest that
further investigations into the use of EVs as biomarkers are
highly warranted for a series of neurological diseases.
Infectious Diseases. The definition of the role of EVs in
the context of infection is still developing, as viruses, bacteria,
fungi, protozoa, and helminths all secrete forms of EVs,
and even prions have been detected in EVs.49,50 Clinically
important pathogens like HIV-1 and hepatitis C and A viruses
use EVs either to alter the host cell or to transport themselves
to host cells. Infected cells can, in turn, release EVs that contain
pathogen-associated molecular patterns (PAMPs) to stimulate
the immune response.51 On the contrary, infectious agents can
use EVs to spread infection, facilitating movement of infectious
materials, and to evade the host immune system response.52
The Leishmania infantum parasite cultivation strategy used
to accumulate exogenous antigens dramatically influences the
composition of the recovered exoproteome, where an enrich-
ment of proteins that are known to be essential for infection,
such as GP63 or EF1, was observed.53 The first in vivo demon-
stration of EV secretion by a pathogen was reported in sand
flies infected with Leishmania major.54 In this study, parasite
EVs were coegested with the parasite during the insect’s bite,
influencing the host’s infectious process and exacerbating
the disease symptoms. Thus, EVs have been proposed as
relevant candidates to add to the repertoire of virulence factors
associated with vector-transmitted infections.54 Thus, there is
great potential for EVs as future biomarkers for infectious
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Autoimmune and Other Diseases. Extracellular vesicles
seem to play key roles in autoimmune diseases. Behcet’s disease
(BD) is a complex multiorgan chronic inflammatory condition
of unknown etiology wherein the genetic background and
environmental factors are thought to be important contributors
to disease pathogenesis.55 In BD patients, plasmapheresis has
been shown to induce rapid short-term remission, suggesting
that an unidentified plasma-associated factor could be a trigger
of flare-ups.56 These patients were found to have elevated EV
numbers in their plasma, and the majority of those EVs were
derived from platelets. It has been proposed that a plasma EV
number-based stratification of BD could more precisely identify
inactive and active disease states and so could aid in its
pharmacological management.
Glycosylation changes of EVs are being considered as disease
biomarkers. In addition, other types of molecules, such as
glycans, have been shown to be EV-linked biomarkers of
different diseases, including some inflammatory and auto-
immune diseases. For example, urinary EVs from patients
with classical galactosemia are characterized by complex-type
N-linked glycosylation in contrast to healthy subjects
whose EV glycosylation was mainly of high-mannose-type.57
Surface glycosylation of urinary EVs was also analyzed in
autosomal dominant polycystic kidney disease (ADPKD).
Here, lectin microarray analysis revealed that 6 out of 43
different lectins have different binding intensity to EVs from
individuals with ADPKD compared to EVs from healthy
subjects.58 All of these findings demonstrate the biomarker
potential of EV glycans and the applicability of high-
throughput techniques (such as lectin microarrays) in
selecting lectins that can be used as the basis for establishing
new diagnostic assays.
NANOSIZED EXTRACELLULAR VESICLES AS
THERAPEUTIC AGENTS
Tumor and Infectious Disease Vaccination. As
described above and previously reviewed,4 EVs from different
cell types exert a variety of different physiological functions.
Initiated with the observation that B-cell-derived EVs carry
functional MHC−peptide complexes on their surface and
contain the potential to exert T cell stimulatory functions,59
interest was raised in using EVs as immune modulatory agents.
After it was shown that EVs derived from dendritic cells (DCs)
pulsed with tumor antigens mediated antitumor responses,60
limited numbers of preclinical and clinical trials investigated
the role of DC-derived EVs as antitumor therapies. So far,
two phase I clinical trials have been performed, one in France
and one in the United States, to treat melanoma or small-cell
lung carcinoma patients, respectively (Table 2).61,62 The trials
mainly demonstrated feasibility and safety; a small number of
patients benefited from the treatment, resulting in the initiation
of a clinical phase II trial in France to treat non-small-cell lung
cancer patients.63 Although the later therapy did not induce
detectable effector T cell responses, a positive effect on natural
killer (NK) cells was observed in some patients.64 Following
the same strategy, EVs from DCs pulsed with pathogens of
infectious disease, such as fungi, bacteria, parasitic protozoa, and
helminths, might be useful as agents in anti-infectious disease
treatment. In fact, proof-of-principle trials have been performed
with DC-EVs obtained from Toxoplasma gondii-pulsed DCs.
Indeed, such EVs conferred protection against subsequent
Toxoplasma infections in preclinical models.65−67 Proof-of-
principle vaccination trials have been also performed in
preclinical animal models for malaria infection. Here, application
of EVs from infected reticulocytes were found to protect
mice from lethal Plasmodium yoelii infections,68 thus reinforcing
the use of EVs as a new therapeutic approach against parasitic
diseases.
Extracellular vesicles have been impli-
cated in various neurodegenerative
diseases including Alzheimer’s disease,
Parkinson’s, and amyotrophic lateral
sclerosis.
Table 2. Therapeutic Application of EVs in Human Clinical Trials and a Treatment Attempt
EV source disease EV modification phase official clinical study title study size ref
dendritic cells pulsed with
antigenic peptides
melanoma phase I n = 15 61




phase I n = 13 62




phase II phase II trial of a vaccination with tumor
antigen-loaded dendritic cell-derived
exosomes on patients with unresectable
non-small-cell lung cancer responding to
induction chemotherapy
n = 22 NCT0115928864
ascites colorectal
cancer
phase I n = 40 74
MSCs type I diabetes phase I phase I study of the effect of cell-free cord blood
derived microvesicles on β-cell mass in type 1
diabetes mellitus (T1DM) patients
n = 20 NCT02138331
MSCs GvHD treatment
attempt
n = 1 76
plant nanovesicles colon cancer curcumin loaded phase I phase I clinical trial investigating the ability of
plant exosomes to deliver curcumin to normal
and malignant colon tissue






phase II phase II study of tumor cell-derived
microparticles used as vectors of
chemotherapeutic drugs to treat malignant
ascites and pleural effusion
n = 22 NCT01854866
ACS Nano Perspective
DOI: 10.1021/acsnano.5b08015
ACS Nano XXXX, XXX, XXX−XXX
F
In other settings, EVs directly released from pathogens or
from pathogen-infected cells have been used to pulse DCs
in vitro or for subsequent in vivo vaccination in a number of
preclinical models.6,69 In a similar context, outer membrane
vesicles (OMVs), which are continuously produced by Gram-
negative bacteria by vesiculation of the outer membrane,70 have
successfully been used as vaccines.71 For example, an OMV-
based vaccine named Bexsero has been generated by Novartis.
It efficiently protects against Neisseria meningitides infections
and is used as a vaccine against serogroup B meningococcal
diseases in children.72,73 Extracellular vesicles as vaccines have
also been used in antitumor therapy. Specifically, in a phase I
clinical trial performed in China, EVs from ascites fluid from
colorectal cancer patients were used as a vaccine to trigger
antitumor activities of DCs (Table 2). Feasibility and safety
were demonstrated.74 Preclinical and clinical EV-based vaccina-
tion trials for antitumor treatment or to fight infectious diseases
indicate that this therapeutic concept is safe and feasible. The
future will show how this can be translated as nanomedicinal
approaches in clinics.
Immune Suppressive and Regenerative Therapies.
Patient cohorts with a variety of different degenerative and
inflammatory diseases have been treated with somatic stem
cells, especially with mesenchymal stem cells (MSC), either to
promote regeneration or to suppress inflammation.75 Contrary
to the original assumption that stem cells integrate into affected
tissue to exert their therapeutic function, they instead seem to
act in a paracrine rather than in a cellular manner. The results
of increasing numbers of studies in preclinical models and a
single treatment attempt of a graft versus host disease patient
suggest that EVs exert the stem cells’ therapeutic effects.6,76−78
Head-to-head comparisons of MSC and MSC-EV applica-
tions have been performed in animal models for acute kidney
failure79 and ischemic stroke.80 Significant differences were
undetected.
Thus, it is feasible that, in the future, stem-cell-derived EVs
could be used instead of stem cells to treat various diseases.
There are several challenges to be addressed before stem-cell-
derived EVs can be approved for the treatment of certain
diseases, but compared to therapies with stem cells, they provide
a variety of advantages. In contrast to cells as non-self-renewing
units, EVs lack any endogenous tumor-formation potential.
Furthermore, they can be sterilized by filtration through
0.22 μm filters and can be handled, stored, and characterized
more easily than cells. However, it has to be considered that
any given EV samples may provide heterogeneous mixtures of
different EV subentities, all containing different compositions.
For biological activity, heterogeneity may be an important
parameter, as EVs may concomitantly convey multiple signals
that act synergistically for a defined activity. However, this
heterogeneity provides a challenge to the standardization of EV
preparations. Recent findings indicate that EVs released from
stem/progenitor cells promote tissue regeneration by modu-
lation of gene transcription and induction of epigenetic changes
in recipient cells and by delivering growth factors,81 but studies
on the mode of action and identification of potentially healing
molecules carried by EVs are a challenge for the field. Rapid
translation of EV products for therapeutic use is also challenged
by the lack of standard purification and characterization
methods that can be used in clinical settings.6 However, a
number of research groups and companies are working on these
challenges. It is highly likely that stem-cell-derived EVs as well as
EVs from other cell types (e.g., endothelial cell or regulatory
T cells82−87) will advance to clinical applications within the next
few years. Treatments of a range of diseases have been
considered as potentially profiting from EV therapies, including
autoimmune, chronic, and acute inflammatory diseases such as
rheumatoid arthritis, inflammation of connective and vascular
tissues, autoimmune inflammatory disease, intestinal chronic
inflammatory diseases, Crohn’s diseases and ulcerative colitis,
type 1 diabetes, multiple sclerosis, cystic fibrosis, graft versus host
disease, as well as diseases associated with acute tissue damage
such as myocardial infarction, ischemic stroke, acute and chronic
kidney failure, drug-induced liver injury, hypoxia-induced
pulmonary hypertension, hind limb ischemia, and perinatal
asphyxia.6
Further, within the context of EV research, parasites
(including helminths) have been shown to produce EVs
expressing immunomodulatory molecules.50 Such EVs have
been considered for the treatment of autoimmune disorders.88
Indeed, recent studies have shown the usefulness of EVs from
Heligmosomoides polygyrus, a parasitic roundworm, in a rodent
model of allergy.89
Drug Delivery. From an applied perspective, synthetic
lipoproteins have long been considered to be viable nano-
carriers for targeted delivery of drugs90−93 because numerous
cancers overexpress light density lipoprotein receptor. The
most widely exploited drug-delivery platform is based on
liposomes or lipid-based nanoparticles (LNPs). These nano-
formulations have been used effectively to encapsulate various
macromolecular drugs including proteins, chemotherapeutics,
imaging agents, and different species of therapeutic RNAs
(e.g., small interfering RNA, siRNA). Many of these bind to
apolipoprotein E (ApoE) in blood and facilitate efficient
delivery to the liver.92 Despite being effective, the main limita-
tions with current nanocarriers based on LNPs are potential
toxicity/immunogenecity and limited ability to penetrate organs
and tissues outside the reticuloendothelial system (RES). Hence,
EVs have emerged as candidates for drug delivery. Several
reports have indicated the high delivery potential of EVs, such as
paclitaxel in autologous prostate cancer EVs,93 in particular, in
relation to endogenous protein and miRNA transfer.94
Furthermore, they can contain gDNA.95,96 Extracellular vesicles
have also successfully been used to deliver exogenous drugs such
as small molecules, miRNAs, and siRNAs.97 Recently, it was
demonstrated that even an exogenous protein (catalase) can be
loaded into EVs and subsequently confer neuroprotection in
models of Parkinson’s disease.98
By engineering EVs to display targeting moieties, tissues
beyond the RES are amenable to targeting even after systemic
delivery.99,100 Although EVs hold true potential as drug-delivery
platforms, we note that the efficacy of loading of the lipophilic
small drugs is good,94 but in the case of siRNA, it is very low.101
Similarly, in the case of endogenous miRNA transfer with EVs,
caution has to be taken, as the majority of extracellular RNA is
not associated with EVs.102 Thus, strategies are needed that can
increase exogenous drug loading or methods of manipulating
producer cells that permit selective loading of proteins or RNA
into EVs. Examples where loading of drugs (in addition to the
self-assembly of lipophilic drugs) could be achieved include
the use of extruded vesicles from cells as well as synthetic
EVs.103−105 However, it remains to be shown whether such
systems are equally effective and safe as naturally secreted and
purified EVs. In this context, it is interesting to note that
exosomes released from melanocytes and melanoma cells
were recently found to interact physically with ApoE-associated
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lipoparticles, maybe indicating that each of the different
nanomessengers can be combined to make use of each of
their advantages as a drug-delivery tool.106
Nanoparticle PEGylation (PEG is a coiled polymer of
repeating ethylene ether units with dynamic conformations) is
the current standard for stealth in nanoparticle drug delivery.
However, potential immunological response and absence of
active targeting prevent its widespread use.107 PEGylated nano-
particles rely on the enhanced permeability and retention (EPR)
effect for tumor targeting, which is absent if primary tumors
or metastases are smaller than 100 mm3.108 Bioconjugation
approaches of PEGylated nanoparticles with targeting ligands
to self-organize into some useful conformation are ambiguous
because of denaturation of proteins during the conjugation
process and the overall difficulty of duplicating biological
complexity on the nanoscale.109 These disadvantages are largely
absent when functionalizing PLGA (poly(lactic-co-glycolic
acid)), gold, or silicon nanoparticles with cellular plasma
membranes. This has already been successfully demonstrated
with cancer cell membranes to induce an immune response
(i.e., as a vaccination)110 and by leukocyte and erythrocyte
membranes to enhance circulation times (i.e., by avoiding
immune uptake)109,111 and increasing cancer cell specificity.111
These hybrids possess the ease-of-use and flexibility of synthetic
materials, as well as the functionality and complexity of natural
materials. Thus, EV-sized, cell-membrane-camouflaged nano-
particles are a delivery strategy with the potential to improve the
therapeutic efficacy of the treatment of a variety of diseases.
Extracellular Vesicles in Milk. According to epidemio-
logical analysis, human milk is better than artificial infant
formula in allowing appropriate metabolic programming and
protecting the baby against conditions such as type 2 diabetes,
obesity, and hypertension in later life. Purification of EVs from
breast milk has been described.112,113
Breast milk is rich in many bioactive molecules all sent to the
baby in different packaging (e.g., exfoliated cells, microvesicles,
fat globules). Finding and using natural sources of EVs loaded
with bioactive miRNA from mammals will require extensive
effort in purifying and characterizing EVs both from milk and
from digestive fluids of the baby. The design of artificial nano-
particles for breast milk supplementation remains unresolved.
Other Therapeutic Implications. In discussing EVs’
potential for therapy, a number of glycobiological aspects of
EVs are worth mentioning. First, from a fundamental point of
view, glycans (as other molecules) are specifically enriched or
excluded from EVs. The fact that A/B blood group antigens
are excluded from EVs compared to the plasma membrane is
what enables EVs to be used therapeutically.114 Second, from a
technological point of view, specific targeting of EVs loaded
with therapeutics may be accomplished by displaying peptides
on their surfaces. An associated issue is proteolytical degradation
of such peptides in circulation, but this can be prevented by
introducing a glycosylation motif at specific positions, without
influencing protein−target interactions.115 Third, for applica-
tions, specific glyco-profiles of EVs related to several diseases
were detected by lectins, and new adjuvant cancer therapy
strategies employing lectins to remove circulating cancer-derived
EVs selectively have been proposed.116
Extracellular Vesicles in Cosmetics. Recent studies have
highlighted roles for EVs in the skin. Maintenance of skin
pigmentation, which is required for skin color and for photo-
protection against harmful UV radiation, is the consequence of
tight intercellular communication between keratinocytes and
melanocytes. In an academic−industrial collaboration between
the Raposo group and Clarins Laboratories, it was shown that
human primary keratinocytes secrete EVs that are targeted to
melanocytes to modulate pigmentation. Extracellular vesicles
are key actors in skin pigmentation, enhancing melanin synthesis
by increasing the expression and activity of melanosomal
proteins.117 These effects are connected to particular miRNA
compositions. Furthermore, the function of keratinocyte-derived
EVs has been demonstrated to be photo-type-dependent and is
modulated by UVB. This study not only uncovers an important
physiological function for EVs in our understanding of how
pigmentation is regulated by intercellular communication but
also opens new avenues for technological development. For
example, based on these findings, Clarins recently launched a
new product that, likely by acting on the composition of EVs,
inhibits overproduction of melanin (“Seŕum Mission Perfection
de Clarins”).
PRECLINICAL DATA SUPPORT A GREAT FUTURE
FOR NANOSIZED EXTRACELLULAR VESICLES
IN NANOMEDICINE
Based on the clinical evidence (outlined above) showing that
EVs may be exploited as either disease biomarkers or therapeutic
tools, it is conceivable that EVs may represent key players in the
future of nanomedicine and, in particular, in the field aimed at
defining the most biomimetic approach in nanomedicine. The
presence of EVs in the plasma of both healthy individuals and
those with various diseases suggests that EVs may serve as
vectors for transferring information to tissues and organs far from
their places of production, that is, acting in a paracrine manner.
These actions indicate that EVs may well diffuse normal,
abnormal, or aberrant messages to cells both close to their
origins and at distances. This, in turn, suggests that EVs may
play key roles as nanodevices belonging to integrated networks
involved in multiple pathophysiologies. Our current under-
standing is that EVs are key regulators of normal functions of
the body.4
It is conceivable that in the near future nanosized EVs may
be helpful in the screening and diagnosis of viral diseases.
In fact, we have evidence that EVs are natural delivery systems
for a variety of viruses including EBV, HCV, HIV, coxsackie
virus B1, and hepatitis A.118−124 Moreover, prion proteins
are shuttled by nanovesicles, although only preclinical data are
available to date.125−129 The data strongly suggest that
EV-based tests will be included in new screening approaches
for transmissible diseases, for example, in blood donors.
Preclinical data also support the use of EVs as the most
biomimetic nanovectors for a variety of molecules, including
proteins, nucleic acids, and chemicals. Nanosized EV-encapsulated
curcumin, delivered by the intranasal route, is efficient in
preventing brain inflammation and is more effective than
curcumin alone.130 Moreover, EVs released by human tumor
cells or human tumors treated with cisplatin contain cisplatin in
its active/native form.131 The future of the clinical use of EVs
EV-sized, cell-membrane-camouflaged
nanoparticles are a delivery strategy
with the potential to improve the
therapeutic efficacy of the treatment of
a variety of diseases.
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depends on a high level of networking between researchers
involved in the field and a strategic approach on how to guide
future research. A level of consensus was recently achieved by the
International Society for Extracellular Vesicles (ISEV), although it
has not yet been fully implemented in clinical studies.6,132,133
Funded by Europe’s Horizon 2020 program, a consortium of
academic, clinical, and industry partners with a common interest
in EVs has been established. This cooperation in science and
technology, entitled the European Network on Microvesicles
and Exosomes in Health and Disease (ME-HaD), includes EV
researchers from 27 European countries and allied groups from
the United States and Australia. The aim of ME-HaD is to foster
multidisciplinary approaches to research in this field, including
the theranostic relevance of EVs, with the ultimate goal of
exploiting EVs for clinical applications, which is achievable only
through coordinated efforts and valorization. Guided, mentored,
and trained by more experienced EV researchers within
ME-HaD, this consortium currently includes membership of
more than 250 early stage researchers, who will hopefully be the
future leaders in the field of EV research and application.
THE FUTURE OF EXTRACELLULAR VESICLES IN
NANOMEDICINE AND INDUSTRY INVESTMENT
The life science market is remarkably conservative, relative
to the extremely dynamic EV market. For instance, ultra-
centrifugation is still the gold standard for EV isolation, used
by ∼60% of researchers in the field. The acceptance of novel
commercial tools is slow. The pharma industry, however, is
open to EV-based solutions in companion diagnostics and
personalized medicine if they are reliable and specific for EVs.
Thus, EV analysis will likely enable rapid in vitro diagnostic or
laboratory-developed/exoteric tests for hospitals or centralized
laboratories and will also be tools for quality control of produc-
tion processes and surrogate markers for the development of
novel therapies.
1. In order to surmount regulatory hurdles (which are
diverse and rapidly evolving in the biggest markets, such as the
United States, the European Union, and Asia) and both market
and cultural insertion, extensive clinical validation and techno-
logy beta testing is needed. This calls for time, money, and
collaborative research efforts including multiple stakeholders
so as to produce definitive evidence that EV marker assays
outperform and/or complement conventional diagnostics, thus
leading to a broad acceptance from clinicians and patients.
2. The technological readiness level of EV analysis might
not be sufficiently robust. Fabrication of novel materials and
sophisticated devices (microfluidic chips or specific sensors)
has produced some exciting proof-of-concept applications
of advanced technologies. These have limited application in
routine laboratory practice, however, due to cost or because
they still are not guaranteed to work in “all hands”, according
to their inventors. On the other hand, we have convincing
evidence of EV detection and analysis using cost-effective and
familiar formats of assays that are compatible with off-the-shelf
laboratory equipment such as plate readers or polymerase chain
reaction (PCR) cyclers.20,134
Extensive developments in the field of EVs, in particular, the
promising preliminary results from using EVs, therapeutically
and as diagnostics markers, has resulted in a number of start-ups
that have initiated commercialization of these achievements.
Big and small pharmaceutical companies have already taken
first steps in evaluating development, costs of the investments,
and registration and commercialization strategies. Promising
results and demands for new therapeutic EV development will,
undoubtedly, stimulate pharmaceutical industry interest in the
production of therapeutic EVs at larger scales.
The active participation of the pharmaceutical industry
should support the development of the field of EVs. Large
companies, with a high volume of starting material and the
availability of analytical tools, will accelerate development of the
detection and characterization of EVs by both the evaluation
of commonly used techniques and the development of new
techniques. In addition, the pharmaceutical industry’s high
demands for quality regulation will accelerate standardization
of EV sample collection, isolation, and analysis methods, which
are highly desirable outcomes.
CONCLUSIONS AND PROSPECTS
Nanosized EVs, which may both contain disease biomarkers
and/or be the vectors of potential therapeutic molecules, thus
represent the ideal theranostic approach. This new multi-
disciplinary field focuses on building nanosystems for future
joint applications of diagnosis and therapy. The theranostic
“all-in-one approach” has great potential in the field of
personalized medicine, as it enables the detection and
monitoring of a disease in individual patients, possibly in early
clinical stages, as well as targeted drug delivery at the site of the
disease. Here, we have included data dealing with clinical studies
and provided evidence that EVs are currently used in clinical
research as biomarkers of disease and as therapeutic tools. Thus,
this Perspective emphasizes the evidence that natural nanosized
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